Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / PD-1 Blockade in Anaplastic Thyroid Carcinoma.

< BACK TO ARCHIVE


2020 May 04


J Clin Oncol


http://www.ncbi.nlm.nih.gov/pubmed/32364844?dopt=Abstract

PD-1 Blockade in Anaplastic Thyroid Carcinoma.

Authors

PD-1 Blockade in Anaplastic Thyroid Carcinoma.
Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin C-C, Ramlau R, Butler MO, Delord J-P, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke M L, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, et al.
J Clin Oncol. 2020 May 04:JCO1902727.
PMID: 32364844.

Abstract

Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with -wild type disease. As part of a phase I/II study in patients with advanced/metastatic solid tumors, patients with anaplastic thyroid carcinoma were treated with spartalizumab, a humanized monoclonal antibody against the programmed death-1 (PD-1) receptor.
Read This Paper